Trial Profile
Evaluation of safety and effect of four doses level of NAcGM3/VSSP formulation as immunopotentiator by subcutaneous route in the treatment of aids patients drug resistant to antiretroviral treatment. - Not applicable
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs N-acetyl GM3 vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 29 Aug 2016 New trial record